Skip to main content
  • Clinical
      |Clinical
    • Acute Coronary Syndromes
    • Cardiac Surgery
    • Covid-19
    • Heart Failure
    • Heart Health
    • Heart Rhythm
    • Hypertension
    • Interventional Cardiology
    • Mitral Valve
    • Pharmaceutics
    • Structural Heart Disease
    • TAVR
    • Tricuspid Valve
    • Vascular & Endovascular
  • Management
      |Management
    • Chest Pain Guidelines
    • Compensation
    • Economics
    • Education & Training
    • Legal News
    • Patient Care
    • Policy & Regulations
    • Professional Associations
    • Quality
    • Revenue
    • Staffing
  • Technology
      |Technology
    • AI
    • Cardiac Imaging
    • Cath Lab
    • CT
    • CVIS
    • ECG
    • Echo
    • EP Lab
    • Informatics
    • MRI
    • Nuclear Cardiology
    • Remote Monitoring
  • Videos
  • Conferences
      |Conferences
    • ACC
    • AHA
    • ASE
    • ASNC
    • ESC
    • EuroPCR
    • HFSA
    • HRS
    • HRS
    • SCAI
    • SCCT
    • SIIM
    • SNMMI
    • STS
    • TCT
    • VIVA
  • Custom Content
      |Custom Content
    • Experience Stories
    • Webinars & Videos
  • Subscribe
  • Forty Under 40 Award
      |Forty Under 40 Award
    • Class of 2026
    • Class of 2025

Search form

Home

News You Need to Know Today
Week in Review: J&J, Edwards make big moves | The potential impact of higher CCTA payments | Device recalled after death
Saturday, August 24, 2024
Link to Twitter Link to Facebook Link to Linkedin Link to Vimeo

This Week’s News

Johnson & Johnson to acquire heart failure specialists V-Wave for up to $1.7B

V-Wave has gained considerable attention for its Ventura Interatrial Shunt System, a small implantable device designed to reduce pressure on the left atrium and lungs of HFrEF patients.

READ MORE >
V-Wave has gained considerable attention or its Ventura Interatrial Shunt System, a small implantable device designed to reduce pressure on the left atrium and the lungs in patients with heart failure with reduced ejection fraction (HFrEF). The Ventura device includes a nitinol hourglass-shaped frame that anchors to the patient’s fossa ovalis in a way that prevents migration or embolization. It is implanted via an interventional procedure with fluoroscopy and echocardiography guidance.
Share on Twitter Share on Facebook Share on Linkedin

Johnson & Johnson to acquire heart failure specialists V-Wave for up to $1.7B

Share on Twitter Share on Facebook Share on Linkedin
V-Wave has gained considerable attention or its Ventura Interatrial Shunt System, a small implantable device designed to reduce pressure on the left atrium and the lungs in patients with heart failure with reduced ejection fraction (HFrEF). The Ventura device includes a nitinol hourglass-shaped frame that anchors to the patient’s fossa ovalis in a way that prevents migration or embolization. It is implanted via an interventional procedure with fluoroscopy and echocardiography guidance.
V-Wave has gained considerable attention for its Ventura Interatrial Shunt System, a small implantable device designed to reduce pressure on the left atrium and lungs of HFrEF patients.
READ MORE >

Higher payments for CCTA could bring considerable change to cardiology

Ron Blankstein, MD, explains how and why Medicare is proposing an increase to hospital payments for coronary CT angiography.

READ MORE >
Ron Blankstein, MD, FACC, FASNC, MSCCT, FASPC, associate director, cardiovascular imaging program, director, cardiac computed tomography, Brigham and Women’s Hospital, and a professor of medicine and radiology, Harvard Medical School, explains why Medicare is proposing increased coronary computed tomography angiography (CCTA) payments to hospitals.
Share on Twitter Share on Facebook Share on Linkedin

Higher payments for CCTA could bring considerable change to cardiology

Share on Twitter Share on Facebook Share on Linkedin
Ron Blankstein, MD, FACC, FASNC, MSCCT, FASPC, associate director, cardiovascular imaging program, director, cardiac computed tomography, Brigham and Women’s Hospital, and a professor of medicine and radiology, Harvard Medical School, explains why Medicare is proposing increased coronary computed tomography angiography (CCTA) payments to hospitals.
Ron Blankstein, MD, explains how and why Medicare is proposing an increase to hospital payments for coronary CT angiography.
READ MORE >

Edwards continues valve-focused M&A streak by acquiring promising TAVR startup

The move makes it crystal clear that Edwards remains focused on pursuing advanced TAVR technologies. The company just acquired JenaValve, another company dedicated to developing new AR treatments, back in July.

READ MORE >
healthcare business deal
Share on Twitter Share on Facebook Share on Linkedin

Edwards continues valve-focused M&A streak by acquiring promising TAVR startup

Share on Twitter Share on Facebook Share on Linkedin
healthcare business deal
The move makes it crystal clear that Edwards remains focused on pursuing advanced TAVR technologies. The company just acquired JenaValve, another company dedicated to developing new AR treatments, back in July.
READ MORE >

Cardiologists detail world’s first implant of new device for ‘no-option’ chest pain patients

The A-Flux Reducer System by VahatiCor was designed to “conform seamlessly” to any patient’s anatomy, and it can be repositioned or retrieved as necessary.

READ MORE >
Interventional cardiologists in Canada have performed the world’s first implant of a new coronary sinus reducer designed to treat chest pain patients who see no benefits from other available interventional or surgical treatments. The A-Flux Reducer System was designed and developed by VahatiCor, a new medical device company associated with California-based T45 Labs.
Share on Twitter Share on Facebook Share on Linkedin

Cardiologists detail world’s first implant of new device for ‘no-option’ chest pain patients

Share on Twitter Share on Facebook Share on Linkedin
Interventional cardiologists in Canada have performed the world’s first implant of a new coronary sinus reducer designed to treat chest pain patients who see no benefits from other available interventional or surgical treatments. The A-Flux Reducer System was designed and developed by VahatiCor, a new medical device company associated with California-based T45 Labs.
The A-Flux Reducer System by VahatiCor was designed to “conform seamlessly” to any patient’s anatomy, and it can be repositioned or retrieved as necessary.
READ MORE >

FDA approves new AI-powered imaging software from Nanox subsidiary

According to Nanox.AI, previously known as Zebra Medical Vision, the updated software helps "bridge the divide between radiology and cardiology."

READ MORE >
AI cardiology heart artificial intelligence deep learning
Share on Twitter Share on Facebook Share on Linkedin

FDA approves new AI-powered imaging software from Nanox subsidiary

Share on Twitter Share on Facebook Share on Linkedin
AI cardiology heart artificial intelligence deep learning
According to Nanox.AI, previously known as Zebra Medical Vision, the updated software helps "bridge the divide between radiology and cardiology."
READ MORE >

OCT-guided PCI improves survival after life-threatening heart attacks

Researchers explored data from nearly 4,000 STEMI patients, noting that optical coherence tomography may be a valuable first step of any treatment strategy. 

READ MORE >
Images coronary calcium imaging by optical coherence tomography (OCT) and high-definition intravascular ultrasound (IVUS).
Share on Twitter Share on Facebook Share on Linkedin

OCT-guided PCI improves survival after life-threatening heart attacks

Share on Twitter Share on Facebook Share on Linkedin
Images coronary calcium imaging by optical coherence tomography (OCT) and high-definition intravascular ultrasound (IVUS).
Researchers explored data from nearly 4,000 STEMI patients, noting that optical coherence tomography may be a valuable first step of any treatment strategy. 
READ MORE >

FDA clears AI-powered POCUS platform for structural heart disease, heart failure

The cloud-based platform was designed to help even inexperienced users scan and diagnose a majority of common heart issues within minutes without leaving the patient’s side.

READ MORE >
AISAP, an Israeli healthcare technology company focused on using artificial intelligence (AI) to enhance medical imaging results, has gained U.S. Food and Drug Administration (FDA) clearance for its new point-of-care ultrasound (POCUS) software platform, AISAP Cardio.
Share on Twitter Share on Facebook Share on Linkedin

FDA clears AI-powered POCUS platform for structural heart disease, heart failure

Share on Twitter Share on Facebook Share on Linkedin
AISAP, an Israeli healthcare technology company focused on using artificial intelligence (AI) to enhance medical imaging results, has gained U.S. Food and Drug Administration (FDA) clearance for its new point-of-care ultrasound (POCUS) software platform, AISAP Cardio.
The cloud-based platform was designed to help even inexperienced users scan and diagnose a majority of common heart issues within minutes without leaving the patient’s side.
READ MORE >

White House unveils lower prices for popular heart, diabetes drugs after Medicare negotiations

Apixaban, empagliflozin, rivaroxaban and sacubitril/valsartan are just some of the medications included in this initial round of Medicare price negotiations. Their new prices were reduced by 56%, 66%, 62% and 53%, respectively. 

READ MORE >
money business cash flow dollar. Kingsway Financial Services, a Chicago-based holding company with subsidiaries in several industries, has acquired New Jersey-based Digital Diagnostics Imaging (DDI) for $11 million. The transaction was funded with $5.4 million in cash and $5.6 million in debt financing.
Share on Twitter Share on Facebook Share on Linkedin

White House unveils lower prices for popular heart, diabetes drugs after Medicare negotiations

Share on Twitter Share on Facebook Share on Linkedin
money business cash flow dollar. Kingsway Financial Services, a Chicago-based holding company with subsidiaries in several industries, has acquired New Jersey-based Digital Diagnostics Imaging (DDI) for $11 million. The transaction was funded with $5.4 million in cash and $5.6 million in debt financing.
Apixaban, empagliflozin, rivaroxaban and sacubitril/valsartan are just some of the medications included in this initial round of Medicare price negotiations. Their new prices were reduced by 56%, 66%, 62% and 53%, respectively. 
READ MORE >

Automated chest compression device recalled after patient death

Regulators emphasized that these devices should not be used due to significant safety risks. 

READ MORE >
The U.S. Food and Drug Administration (FDA) has announced that Defibtech, a Nihon Kohden company, is recalling its RMU-2000 ARM XR Chest Compression Device due to significant safety concerns. This is a Class I recall, which means the FDA believes using the device “may cause serious injury or death.”
Share on Twitter Share on Facebook Share on Linkedin

Automated chest compression device recalled after patient death

Share on Twitter Share on Facebook Share on Linkedin
The U.S. Food and Drug Administration (FDA) has announced that Defibtech, a Nihon Kohden company, is recalling its RMU-2000 ARM XR Chest Compression Device due to significant safety concerns. This is a Class I recall, which means the FDA believes using the device “may cause serious injury or death.”
Regulators emphasized that these devices should not be used due to significant safety risks. 
READ MORE >

No aspirin, no problem: FDA approves key update for Abbott heart pumps

Patients have typically been told to take aspirin and an oral anticoagulant following treatment to help combat the risk of blood clots. Now, they can skip the aspirin altogether.

READ MORE >
Abbott’s HeartMate 3 left ventricular assist device (LVAD) has been implanted in thousands of U.S. patients in recent years.According to a new investigative report from CBS News and KFF Health News, however, safety data related to the device have raised questions in certain parts of the healthcare industry.
Share on Twitter Share on Facebook Share on Linkedin

No aspirin, no problem: FDA approves key update for Abbott heart pumps

Share on Twitter Share on Facebook Share on Linkedin
Abbott’s HeartMate 3 left ventricular assist device (LVAD) has been implanted in thousands of U.S. patients in recent years.According to a new investigative report from CBS News and KFF Health News, however, safety data related to the device have raised questions in certain parts of the healthcare industry.
Patients have typically been told to take aspirin and an oral anticoagulant following treatment to help combat the risk of blood clots. Now, they can skip the aspirin altogether.
READ MORE >

Innovate Healthcare thanks our partners for supporting our newsletters.
Sponsorship has no influence on editorial content.

Interested in reaching our audiences, contact our team

*|LIST:ADDRESSLINE|*

You received this email because you signed up for newsletters from Innovate Healthcare.
Change your preferences or unsubscribe here

Contact Us  |  Unsubscribe from all  |  Privacy Policy

© Innovate Healthcare, a TriMed Media brand
Innovate Healthcare

Recent Newsletters

Medtech giant makes big move | The world’s top hospitals for heart surgery | New CPT codes | PET vs. SPECT | TAVR tech recalled
AI is gaining ground, but clinicians run the show | Siemens Healthineers doubles down | Electrophysiologist compensation
News Alert: FDA shares warning about heart valve tech after patient death
Cardiologist pay & productivity are up | FDA clears PE thrombectomy devices | Cardiology tech in spotlight | Gore's new approval
Cardiology salaries on the rise | The climbing costs of care | M&A trends | Siemens Healthineers, J&J make big business moves
Major MRI trends | Blood thinner recalled | When to perform PCI before TAVR | How to build a CCTA program | Steroids & the heart
CMS boosts coverage for heart failure tech | FDA approves CardioMEMS updates | LVADs linked to strokes, other risks
Newsletter archive
  • Home
  • News
  • Article Archive
  • Custom Content
  • Webinars
  • Press Releases
  • Content Studio
  • Advertising
  • Submit Press Release
  • Contact Us
  • Terms of Use
  • Privacy Policy
  • Cardiovascular Business
  • HealthExec
  • Radiology Business
  • Press Releases
  • Submit Press Release
© 2026 Innovate Healthcare | All Rights Reserved. | Terms of Use | Privacy Policy
Design by Adaptive Theme
Trimed Popup